Breakthrough reveals how heart rhythm disorders develop at molecular level

Scientists have uncovered key molecular mechanisms controlling the gating of cardiac KCNQ1-KCNE1 channels. These findings shed light on how disruptions in the channel's structure and lipid interactions contribute to life-threatening heart rhythm disorders.

The study highlights two distinct binding sites for PIP₂, a membrane lipid, which work together to regulate channel function with precision.

The KCNQ1-KCNE1 channel contains two separate PIP₂ binding sites that each play a unique role. One site promotes the channel's opening, while the other reinforces its structural integrity. This dual mechanism ensures the channel operates smoothly, maintaining stable electrical signalling in the heart.

Researchers also found that secondary structural elements—such as alpha helices and beta sheets—undergo dynamic shifts during gating. These transitions are essential for the channel's ability to open and close properly. When mutations or lipid imbalances interfere with either PIP₂ binding or these structural changes, the channel's function becomes unstable, increasing the risk of arrhythmias.

Certain genetic variants linked to hereditary long QT syndrome (LQTS1) disrupt either PIP₂ interactions or the structural transitions needed for normal gating. The study explains why patients with these mutations experience irregular heart rhythms, providing a clear molecular basis for the observed clinical patterns.

Current research is exploring targeted treatments based on these discoveries. One approach involves PIP₂-mimicking small molecules, like ML277 derivatives, which help stabilize the channel's open state in LQTS1 patients. Another strategy uses CRISPR-Cas9 gene therapy to correct KCNQ1 mutations, with Phase I trials already underway since 2024. For acquired rhythm disorders, such as ventricular tachycardia in heart failure, scientists are testing allosteric modulators and KCNE1-specific peptides to enhance the IKs current.

These findings suggest that future therapies could be tailored to a patient's specific lipid profile and genetic background. By adjusting PIP₂ binding or reinforcing beneficial structural conformations, clinicians may develop more effective antiarrhythmic treatments.

The discovery of dual PIP₂ binding sites and dynamic structural changes in KCNQ1-KCNE1 channels offers new avenues for treating heart rhythm disorders. Targeted pharmacological agents and gene therapies are now being tested in clinical settings.

If successful, these approaches could lead to personalised interventions that address the root causes of arrhythmias in individual patients.